Hatch-Waxman's boldest incentive rewards the first ANDA filer to make a Paragraph IV certification on a drug, the first company to attack the patent legally. If it wins or settles and then launches, it earns 180 days of generic market exclusivity. For six months yours is the only generic on the shelf. Usually there's one more, the innovator's own authorized generic, which is the brand product relabeled and launched to eat into your window. Expect it.
Why is the 180-day window worth so much?
Why is the window worth so much? During exclusivity there are effectively two sellers, so the sole generic prices at only a 10–30% discount to brand. It still captures 40–80% of prescriptions within weeks, because US pharmacy substitution is automatic in most states. After day 181 the crowd arrives and price collapses 80–95%. Those six months of exclusivity can be worth more than the following decade of that molecule's sales combined.
Advertisement
Worked example: the exclusivity P&L (synthetic, but modeled on the atorvastatin pattern). Take a brand drug called "Cardexa," with US brand sales of $2,400m/yr. Meridian Pharma (synthetic) is the sole first-to-file, and it wins at trial and launches.
The 180-day window (six months):
- Six months of brand-equivalent volume = $1,200m at brand prices.
- Meridian prices at a 25% discount and captures 45% of volume. The authorized generic takes ~30%, and the brand keeps ~25% of loyalists.
- Meridian revenue = $1,200m × 45% ÷ (1) × 0.75 price factor = $405m.
- COGS ≈ 12%, since it's a cheap-to-make oral solid, so gross profit ≈ $356m.
- Subtract the price of admission. Litigation costs $20–40m over the case's life. Had Meridian launched before final judgment, it would also carry at-risk-launch exposure, potentially damages at brand margins if it lost. That's what makes an at-risk launch a bet-the-company decision.
- Call it roughly $320m of windfall gross profit in six months.
Day 181 onward: eight entrants arrive within a quarter. Price settles at ~10% of brand and Meridian holds a 15% volume share. Annual revenue = $2,400m × 15% × 0.10 = $36m/yr, with gross profit of perhaps $18m/yr, still eroding.
The window produced ~$320m. The annuity produces ~$18m a year, and it's shrinking. So the exclusivity is ~10–18x the annuity, a lottery ticket stapled to a subscription.
For a real-world anchor, take the industry's legend. Ranbaxy's generic atorvastatin (Lipitor, launched November 2011) brought in something on the order of half a billion dollars of revenue in six months (illustrative, ~2011–12 scale, so read the case itself). More recently, volume-limited settlements on generic lenalidomide (Revlimid) pushed several Indian companies' US earnings visibly upward from 2022, Dr Reddy's and Natco most prominently. Just as the model predicts, the market spent those years asking "what happens when gRevlimid fades?" (illustrative, modeled on ~FY23–FY25 disclosures, so pull the actual filings).
How do you value the windfall, and what about settlements?
How to value a windfall: the rule. An exclusivity, or any time-boxed settlement-limited launch, is a one-time cash flow. Value it at ~1× its post-tax profit and add that to the base business's value. Someone commits the cardinal sin every cycle. They leave the windfall inside "EPS," apply the company's 25x P/E to it, and capitalize six months of luck into a permanent valuation. So when a generics company's earnings spike, your first move is to rebuild the P&L without the windfall product. Management usually discloses enough to do it. If it doesn't, triangulate from IQVIA-style market data or the erosion arithmetic. You'll meet the same reflex again in diagnostics, wearing a COVID mask.
Settlements are the quieter, commoner path. Most Para IV cases end in settlement, with the generic getting a licensed entry date before patent expiry (sometimes volume-capped, as with lenalidomide). Settled entry dates are gold for you, because they turn litigation uncertainty into a dated revenue pipeline you can model. Build a table: molecule, brand size, entry date, expected competitors at entry. That table is the US business's three-year forecast. One caution, though. "Pay-for-delay" settlements, cash paid to keep the generic out, have drawn antitrust fire for years. Treat any settlement whose economics you can't see as a governance yellow flag.